- Trial phase
- Phase 1/2
- Time to market
- Likely several years away. LYL273 is in Phase 1/2 dose-finding. The End-of-Phase 1 FDA meeting is expected in 2027, after which a potential pivotal Phase 2 trial would need to enroll and read out before any BLA submission, likely no earlier than 2028-2029 if all goes well.
- Why 4/10
- LYL273's next catalysts are additional Phase 1 clinical data and an End-of-Phase 1 FDA meeting, both now expected in 2027 (no specific date given). With no hard dated binary catalyst within the next ~12 months, and LYL273 being Lyell's secondary program behind ronde-cel (the primary value driver), the impact score is limited to 4.
The next catalysts for LYL273 are additional Phase 1 clinical data and an End-of-Phase 1 meeting with the FDA, both now expected in 2027 (pushed from H2 2026). Positive data and regulatory alignment could open a path to a pivotal Phase 2 trial; a safety or efficacy miss would significantly damage the program's prospects. However, Lyell's primary near-term value driver is ronde-cel (BLA submission H2 2027), so LYL273 updates are secondary for the stock.
Price Chart
Executive Summary
LYL273 (formerly GCC19CART) is a next-generation CAR T-cell therapy targeting guanylyl cyclase C (GCC) for metastatic colorectal cancer (mCRC), acquired by Lyell Immunopharma from Innovative Cellular Therapeutics in November 2025. Early Phase 1 data showed a 67% overall response rate at the highest dose level (6 patients) and a 50% ORR across dose levels 1 and 2. A June 2026 safety update demonstrated improved tolerability with a GI prophylaxis regimen. However, the program's timeline has slipped: the End-of-Phase 1 FDA meeting and additional clinical data were pushed from H2 2026 to 2027 (announced September 2026). LYL273 is Lyell's second clinical asset behind lead candidate ronde-cel (for large B-cell lymphoma), which is the company's primary near-term value driver with a BLA submission planned for H2 2027.
How It Works
LYL273 is a CAR T-cell therapy, a personalized cancer treatment made from a patient's own immune cells. The patient's T cells (a type of white blood cell) are collected, genetically modified in a lab to recognize a protein called guanylyl cyclase C (GCC) found on colorectal cancer cells, and then infused back into the patient. LYL273 includes two additional engineering features: it also expresses a CD19-targeting CAR to help the cells expand better in the body, and it has controlled cytokine release to reduce side effects. The goal is to help the modified T cells find, infiltrate, and kill solid tumors.
Trial Status
The CARABiNER trial (NCT05319314) is an ongoing Phase 1/2 open-label, multicenter study in relapsed/refractory metastatic colorectal cancer. As of May 5, 2026, 19 patients had been enrolled across Dose Levels 1 and 2. The Phase 1 dose-escalation portion is determining the recommended Phase 2 dose; the Phase 2 portion will expand enrollment in a single-arm cohort. Manufacturing transfer to Lyell's Bothell, WA facility was completed in September 2026.
The Two-Sided Case
Upcoming Catalysts
- Additional Phase 1 clinical data including efficacy outcomes (expected 2027)
- End-of-Phase 1 meeting with the FDA (expected 2027)
- Potential expansion into Phase 2 pivotal single-arm trial pending regulatory alignment
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Lyell Immunopharma, Inc Press Release LYEL ·Originating report